LabConnect, LLC announces the release of its BioVisualization software platform.
LabConnect, LLC., a leading provider of central laboratory services to the biopharmaceutical industry, announces the release of its BioVisualization software platform.
LabConnect’s BioVisualization is a proprietary and customizable software platform that queries clinical sample database(s) in real time to analyze and provide visual interpretations of a project’s data. This unique platform is designed to quickly generate customizable figures, which can be downloaded and shared among colleagues and incorporated into reporting documents.
“Large, complex datasets generated throughout the course of a clinical trial make finding underlying trends challenging,” said Eric Hayashi, president and CEO. “LabConnect’s BioVisualization tool makes it possible to visualize this data and find greater meaning using fewer resources. This inventive platform creates an opportunity to make critical decisions a lot sooner.”
LabConnect’s white paper, “BioVisualization: Custom Approaches to Enhance Clinical Data Mining,” provides an overview of visual data analysis tools, their benefits and how this technology is being implemented by pharmaceutical companies of all sizes to make critical decisions faster and with lower costs. This informative white paper is now available for download.
“The scale of datasets has become overwhelming, making analysis of this information tedious and resource-draining,” said Hermioni Zouridis, senior scientist of scientific operations at LabConnect. “Unlike pre-programmed platforms, versatile visual data analytics tools enable researchers to generate customizable figures, helping identify trends in study results faster and ultimately making it possible to bring drugs to market sooner.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.